LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial

What Was Tested

The paper reports a study of Liraglutide, published as a randomized controlled trial.

The researchers used the baseline data of liraglutide effect and action in diabetes: evaluation of CV outcome results-A long term Evaluation (LEADER) (a clinical trial to assess the CV safety of liraglutide) to investigate: (i) prevalence of overweight and obesity; (ii) relationship of the major cardiometabolic risk factors with anthropometric measures of adiposity [body mass index (BMI) and waist circumference (WC)]; and (iii) cardiometabolic treatment intensity in relation to BMI and WC.

Why It Was Studied

Epidemiological data on obesity are needed, particularly in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular (CV) risk.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

LEADER enrolled two distinct populations of high-risk patients with T2DM in 32 countries: (1) aged ≥50 years with prior CV disease; (2) aged ≥60 years with one or more CV risk factors.

Associations of metabolic variables, demographic variables and treatment intensity with anthropometric measurements (BMI and WC) were explored using regression models (ClinicalTrials.gov identifier: NCT01179048).

How the Study Was Run

The design is described as randomized and double-blind.

The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Liraglutide.

What Was Measured

The subject headings attached to it are Body Mass Index, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Liraglutide, Metabolic Syndrome and Obesity.

What This Means in Plain Language

The paper is a randomized and double-blind study of Liraglutide.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Cardiovascular diabetology), a journal based in England.

More context: the Liraglutide compound page.